Cost-Effectiveness of Adjuvanted Influenza Vaccine in Older Adults in the Netherlands
Replacing the standard influenza vaccine with the adjuvanted version in older adults could save €4.3-12.8 million and gain 2,220-6,659 QALYs.
Asset / Drug
Drug and asset intelligence for Cost-Effectiveness with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.